Welcome to our dedicated page for SPRBD SEC filings (Ticker: SPRBD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on SPRBD's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into SPRBD's regulatory disclosures and financial reporting.
Spruce Biosciences (SPRB) ownership update: Alyeska Investment Group, L.P. and related filers report beneficial ownership of 61,670 shares of common stock, equal to 4.49% of the class as of March 31, 2026. The holding comprises 21,671 common shares, 9,999 shares issuable upon exercise of warrants, and 30,000 shares acquired in a private placement. The filing cites 1,372,043 shares outstanding per a Form 424B5 dated March 9, 2026. Alyeska Investment Group, L.P. discloses shared voting and dispositive power for the 61,670 shares, and Anand Parekh is identified as CEO of Alyeska Investment Group, L.P.; he disclaims beneficial ownership of certain shares held by Alyeska Master Fund, L.P.
Spruce Biosciences (SPRB) ownership update: Alyeska Investment Group, L.P. and related filers report beneficial ownership of 61,670 shares of common stock, equal to 4.49% of the class as of March 31, 2026. The holding comprises 21,671 common shares, 9,999 shares issuable upon exercise of warrants, and 30,000 shares acquired in a private placement. The filing cites 1,372,043 shares outstanding per a Form 424B5 dated March 9, 2026. Alyeska Investment Group, L.P. discloses shared voting and dispositive power for the 61,670 shares, and Anand Parekh is identified as CEO of Alyeska Investment Group, L.P.; he disclaims beneficial ownership of certain shares held by Alyeska Master Fund, L.P.
Spruce Biosciences ownership update: Squadron Master Fund LP, Squadron Capital Management, LLC and principals Matthew Sesterhenn and William Blank each report beneficial ownership of 12,200 shares of common stock, representing 0.9% of the class. The filings state these shares reflect shared voting and dispositive power, with no sole voting or dispositive power. The ownership percentage is based on 1,372,043 shares outstanding as of March 3, 2026. The statement includes an express disclaimer of beneficial ownership under Rule 13d-4. The amendment is signed by reporting persons on 05/15/2026.
Spruce Biosciences ownership update: Squadron Master Fund LP, Squadron Capital Management, LLC and principals Matthew Sesterhenn and William Blank each report beneficial ownership of 12,200 shares of common stock, representing 0.9% of the class. The filings state these shares reflect shared voting and dispositive power, with no sole voting or dispositive power. The ownership percentage is based on 1,372,043 shares outstanding as of March 3, 2026. The statement includes an express disclaimer of beneficial ownership under Rule 13d-4. The amendment is signed by reporting persons on 05/15/2026.
Spruce Biosciences, Inc. (Common Stock, CUSIP 85209E208) is reported as being beneficially owned in part by Wellington Management entities. The filing shows a 3.56% beneficial ownership position represented by shared voting power of 34,769 shares and shared dispositive power of 48,796. The Schedule 13G/A states these securities are owned of record by clients of Wellington Investment Advisers and lists the chain of parent and affiliate entities. The filing was signed by a compliance manager on 05/15/2026.
Spruce Biosciences, Inc. (Common Stock, CUSIP 85209E208) is reported as being beneficially owned in part by Wellington Management entities. The filing shows a 3.56% beneficial ownership position represented by shared voting power of 34,769 shares and shared dispositive power of 48,796. The Schedule 13G/A states these securities are owned of record by clients of Wellington Investment Advisers and lists the chain of parent and affiliate entities. The filing was signed by a compliance manager on 05/15/2026.
Spruce Biosciences reported a Q1 2026 net loss of $12.3 million, narrower than the $14.0 million loss a year earlier, as research and development spending declined. R&D totaled $7.6 million versus $10.8 million in Q1 2025, while general and administrative expenses rose to $4.4 million from $3.7 million.
As of March 31, 2026, Spruce held $54.1 million in cash and cash equivalents and had an accumulated deficit of $301.5 million. It also carried $16.6 million in gross debt under a new Avenue term loan, with $15.0 million funded at a 12.25% interest rate and secured by substantially all assets.
The company closed an April 2026 underwritten offering of 1,150,000 common shares and 50,000 pre-funded warrants, plus 180,000 additional shares from the underwriters’ option, for gross proceeds of about $69.0 million. Management believes existing cash plus these proceeds will fund planned operations and debt obligations for at least 12 months.
Spruce is focused on tralesinidase alfa enzyme replacement therapy (TA‑ERT) for mucopolysaccharidoses type IIIB, which has U.S. and EU orphan and breakthrough designations. The company plans to submit a biologics license application for TA‑ERT in the fourth quarter of 2026 and continues preclinical and clinical work on other candidates.
Spruce Biosciences reported a Q1 2026 net loss of $12.3 million, narrower than the $14.0 million loss a year earlier, as research and development spending declined. R&D totaled $7.6 million versus $10.8 million in Q1 2025, while general and administrative expenses rose to $4.4 million from $3.7 million.
As of March 31, 2026, Spruce held $54.1 million in cash and cash equivalents and had an accumulated deficit of $301.5 million. It also carried $16.6 million in gross debt under a new Avenue term loan, with $15.0 million funded at a 12.25% interest rate and secured by substantially all assets.
The company closed an April 2026 underwritten offering of 1,150,000 common shares and 50,000 pre-funded warrants, plus 180,000 additional shares from the underwriters’ option, for gross proceeds of about $69.0 million. Management believes existing cash plus these proceeds will fund planned operations and debt obligations for at least 12 months.
Spruce is focused on tralesinidase alfa enzyme replacement therapy (TA‑ERT) for mucopolysaccharidoses type IIIB, which has U.S. and EU orphan and breakthrough designations. The company plans to submit a biologics license application for TA‑ERT in the fourth quarter of 2026 and continues preclinical and clinical work on other candidates.
Spruce Biosciences reported a first quarter 2026 net loss of $12.3 million, or $(8.94) per share, improving from a $14.0 million loss a year earlier as total operating expenses fell to $12.0 million from $14.5 million on lower R&D spending.
Cash and cash equivalents were $54.1 million as of March 31, 2026 and approximately $107.3 million as of April 30, 2026, supported by a $69.0 million underwritten equity offering and a term loan facility of up to $50.0 million. The company expects this liquidity, together with the April financing, to fund planned operations and debt obligations into the second half of 2027 as it advances its lead therapy TA‑ERT toward a planned BLA submission in the fourth quarter of 2026.
Spruce Biosciences reported a first quarter 2026 net loss of $12.3 million, or $(8.94) per share, improving from a $14.0 million loss a year earlier as total operating expenses fell to $12.0 million from $14.5 million on lower R&D spending.
Cash and cash equivalents were $54.1 million as of March 31, 2026 and approximately $107.3 million as of April 30, 2026, supported by a $69.0 million underwritten equity offering and a term loan facility of up to $50.0 million. The company expects this liquidity, together with the April financing, to fund planned operations and debt obligations into the second half of 2027 as it advances its lead therapy TA‑ERT toward a planned BLA submission in the fourth quarter of 2026.
Spruce Biosciences ownership update: Ikarian Capital, LLC and Neil Shahrestani report shared beneficial ownership of 121,356 shares of Common Stock, representing 4.8% of the class.
The percentage is calculated using 2,522,043 shares outstanding as of April 22, 2026, per the Issuer's prospectus. The filing states these shares are held by Ikarian Healthcare Master Fund, L.P. and certain managed accounts, with Ikarian Capital exercising investment discretion and Mr. Shahrestani deemed to indirectly control Ikarian Capital.
Spruce Biosciences ownership update: Ikarian Capital, LLC and Neil Shahrestani report shared beneficial ownership of 121,356 shares of Common Stock, representing 4.8% of the class.
The percentage is calculated using 2,522,043 shares outstanding as of April 22, 2026, per the Issuer's prospectus. The filing states these shares are held by Ikarian Healthcare Master Fund, L.P. and certain managed accounts, with Ikarian Capital exercising investment discretion and Mr. Shahrestani deemed to indirectly control Ikarian Capital.
Spruce Biosciences, Inc. ownership disclosure: ExodusPoint entities and Michael Gelband report shared beneficial ownership of 22,000 shares of Common Stock. The statement says these shares are held by ExodusPoint Partners Master Fund and that, as of April 27, 2026, each reporting person may be deemed to beneficially own approximately 0.8% of the outstanding class.
The filing states ExodusPoint Capital Management retains investment and voting power over the fund's holdings, ExodusPoint Capital Partners is the fund's general partner, and Mr. Gelband controls both entities. A Joint Filing Agreement is attached as Exhibit 1.
Spruce Biosciences, Inc. ownership disclosure: ExodusPoint entities and Michael Gelband report shared beneficial ownership of 22,000 shares of Common Stock. The statement says these shares are held by ExodusPoint Partners Master Fund and that, as of April 27, 2026, each reporting person may be deemed to beneficially own approximately 0.8% of the outstanding class.
The filing states ExodusPoint Capital Management retains investment and voting power over the fund's holdings, ExodusPoint Capital Partners is the fund's general partner, and Mr. Gelband controls both entities. A Joint Filing Agreement is attached as Exhibit 1.
Spruce Biosciences is offering 1,150,000 shares of common stock and pre-funded warrants to purchase 50,000 shares. The offering prices are $50.00 per share and $49.99 per pre-funded warrant, with expected gross proceeds of $59,999,500 before underwriting discounts. Net proceeds are estimated at approximately $55.9 million, intended to fund pre-commercial and launch activities, planned clinical trials, working capital, capital expenditures and general corporate purposes.
The pre-funded warrants have a $0.01 exercise price, do not expire, are not expected to be listed, and include beneficial-ownership exercise limits (4.99% default, electable to 9.99%). The underwriters have a 30-day option to purchase up to 180,000 additional shares.
Spruce Biosciences is offering 1,150,000 shares of common stock and pre-funded warrants to purchase 50,000 shares. The offering prices are $50.00 per share and $49.99 per pre-funded warrant, with expected gross proceeds of $59,999,500 before underwriting discounts. Net proceeds are estimated at approximately $55.9 million, intended to fund pre-commercial and launch activities, planned clinical trials, working capital, capital expenditures and general corporate purposes.
The pre-funded warrants have a $0.01 exercise price, do not expire, are not expected to be listed, and include beneficial-ownership exercise limits (4.99% default, electable to 9.99%). The underwriters have a 30-day option to purchase up to 180,000 additional shares.
Spruce Biosciences, Inc. is offering shares of its common stock and pre-funded warrants to purchase common stock in a registered primary offering under its shelf registration. The pre-funded warrants have a $0.01 exercise price and do not expire; they are offered in lieu of common stock to certain investors. The prospectus discloses liquidity limits for the pre-funded warrants (no exchange listing expected), an ownership exercise limitation (4.99% default, electable up to 9.99%), and that net proceeds will be used for pre-commercial and launch activities, planned clinical trials, working capital and general corporate purposes. The document also states key capitalization figures as of December 31, 2025 and references an ATM Program with capacity up to $75.0 million.
Spruce Biosciences, Inc. is offering shares of its common stock and pre-funded warrants to purchase common stock in a registered primary offering under its shelf registration. The pre-funded warrants have a $0.01 exercise price and do not expire; they are offered in lieu of common stock to certain investors. The prospectus discloses liquidity limits for the pre-funded warrants (no exchange listing expected), an ownership exercise limitation (4.99% default, electable up to 9.99%), and that net proceeds will be used for pre-commercial and launch activities, planned clinical trials, working capital and general corporate purposes. The document also states key capitalization figures as of December 31, 2025 and references an ATM Program with capacity up to $75.0 million.
Spruce Biosciences, Inc. will hold its 2026 virtual annual meeting of stockholders on May 21, 2026 at 10:00 a.m. Pacific Time. Holders of 1,372,278 shares of common stock as of March 24, 2026 may vote online.
Stockholders will vote on electing three Class III directors to terms ending at the 2029 annual meeting, ratifying BDO USA, P.C. as independent auditor for 2026, approving on an advisory basis executive compensation, and choosing how often future advisory pay votes should occur. The filing also explains a previously effected 1-for-75 reverse stock split, board independence and structure, committee memberships, ownership of major holders and insiders, and key governance policies, including an insider trading policy and clawback framework.
Spruce Biosciences, Inc. will hold its 2026 virtual annual meeting of stockholders on May 21, 2026 at 10:00 a.m. Pacific Time. Holders of 1,372,278 shares of common stock as of March 24, 2026 may vote online.
Stockholders will vote on electing three Class III directors to terms ending at the 2029 annual meeting, ratifying BDO USA, P.C. as independent auditor for 2026, approving on an advisory basis executive compensation, and choosing how often future advisory pay votes should occur. The filing also explains a previously effected 1-for-75 reverse stock split, board independence and structure, committee memberships, ownership of major holders and insiders, and key governance policies, including an insider trading policy and clawback framework.